2025, BMI and Thrombosis - Cardiovascular Update

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2025

BMI

Thrombosis

Study Demonstrates Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age, Bleeding Risk

DAIC

MARCH 31, 2025

tim.hodson Mon, 03/31/2025 - 16:38 March 29, 2025 Anthos Therapeutics, Inc., In addition, abelacimab consistently reduced bleeding risk in patients 75 years of age and older regardless of renal function, body mass index (BMI), and the use of concomitant antiplatelet therapy. The ARR in patients 75 years of age and older was 6.2%

Atrial Fibrillation

Atrial Fibrillation BMI General Cardiology Thrombosis

Abstract TP268: Xylitol, Xylose, and MicroRNAs Associated with Thrombosis and the Clotting Cascade in a Multi-Omics Cross-Sectional Study of Adults at Risk for Type 2 Diabetes and Stroke

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP268-ATP268, February 1, 2025. Introduction:Xylitol, a sugar alcohol with a global market estimated at 161,500 metric tons, has been linked to increased thrombosis and risk of stroke and heart attack. The mean BMI was 35.2 kg/m2, HbA1c was 5.9% 0.4,

Thrombosis

Thrombosis Obesity Stroke Strokes

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Study Demonstrates Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age, Bleeding Risk

Abstract TP268: Xylitol, Xylose, and MicroRNAs Associated with Thrombosis and the Clotting Cascade in a Multi-Omics Cross-Sectional Study of Adults at Risk for Type 2 Diabetes and Stroke

Webinars

Stay Connected